Bid - BH3 interacting domain death agonist Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 64625

Summary

Predicted to enable ubiquitin protein Ligase binding activity. Involved in several processes, including positive regulation of Autophagy in response to ER overload; release of cytochrome c from mitochondria; and response to ischemia. Located in cytosol and mitochondrion. Used to study pre-malignant neoplasm. Human ortholog(s) of this gene implicated in pancreatic Cancer. Orthologous to human BID (BH3 interacting domain death agonist). [provided by Alliance of Genome Resources, Apr 2022]

Bid Products (1)

mRNA Protein Name
NM_022684.2 NP_073175.1 BH3-interacting domain death agonist

Gene Ontology

  • Molecular Function
  • Biological Process
Molecular Function GO Annotation Evidence Verweise Source
enables protein binding IPI
IPI: Inferred from physical interaction
12871587 RGD
Biological Process GO Annotation Evidence Verweise Source
involved in glial cell apoptotic process IEP
IEP: Inferred from expression pattern
18931364 RGD
involved in positive regulation of autophagy in response to ER overload IMP
IMP: Inferred from mutant phenotype
25772147 RGD
involved in release of cytochrome c from mitochondria IDA
IDA: Inferred from direct assay
18252800 RGD
involved in response to estradiol IEP
IEP: Inferred from expression pattern
20803709 RGD
involved in response to ischemia IEP
IEP: Inferred from expression pattern
11934844 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

BH3-interacting domain death agonist

  • apoptotic death agonist BID

  • desmocollin type 4

  • p22 BID

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (2)
Art. -Nr. Produktname Wirkung
Reinheit Rare Diseases
HY-B0493 Niflumic acid Inhibitor 99.61% Unkown
HY-B0493R Niflumic acid (Standard) Inhibitor 99.93% Unkown

Clinical Phase

Bioactive Molecules (1)
Art. -Nr. Produktname Wirkung
Reinheit Phase
HY-165550 Sphingosine / Phase 1

Pre-clinical Phase

Bioactive Molecules (26)
Art. -Nr. Produktname
Wirkung
Reinheit
Rare Diseases
HY-10510 BI-D1870 99.43% Unkown
HY-103661 BI-6C9 Inhibitor 98.47% Unkown
HY-N0559 Kirenol 99.82% Unkown
HY-108610A Edelfosine 99.0% Unkown
HY-N6005 Methyl caffeate 99.89% Unkown
HY-125305 Z-AEVD-FMK Inhibitor 95.0% Unkown
HY-18601 (±)-BI-D Inhibitor 98.06% Unkown
HY-167881 MLS-0053105 Inhibitor 98.89% Unkown
HY-121683 (E)-2-Hexadecenal 99.9% Unkown
HY-P5325A Bid BH3 (80-99) acetate 98.13% Unkown
HY-RS01502 BID Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-123244 YC137 / Unkown
HY-162642 Bfl-1-IN-3 Inhibitor / Unkown
HY-N0559R Kirenol (Standard) / Unkown
HY-N17676 3-Tridecylphenol / Unkown
HY-N7917 Tenacigenoside A / Unkown
HY-N8617 Trijuganone C / Unkown
HY-P10614 Bid BH3 peptide Inducer / Unkown
HY-P10614A Bid BH3 peptide acetate Inducer 98.13% Unkown
HY-P11374 Bid BH3-Gly-r8 Ligand / Unkown
HY-P5325 Bid BH3 (80-99) / Unkown
HY-P5325F Bid BH3 (80-99), FAM labeled / Unkown
HY-P5327 r8 Bid BH3 / Unkown
HY-183402 FLLL12 / Unkown
HY-RS16655 Bid Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23090 Bid Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Bid NCBI NCBI:637